MedPath

Contribution of Optical Coherence Tomography in the Endovascular Treatment of Femoral Occlusions

Not Applicable
Conditions
Claudication
Superficial Femoral Artery Stenosis
Ischemic Leg
Registration Number
NCT04434586
Lead Sponsor
University Hospital, Lille
Brief Summary

This is a common care study. A study for evaluating the quality of balloon inflation and stent application will be performed in 2D angiography alone in the control group and then by 2D and OCT angiography for the experimental group. The benefit could be an improvement in the results of revascularization of femoropopliteal lesions thanks to OCT which allows a 3D visualization of the arterial lumen.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
166
Inclusion Criteria
  • Patient over 18 years old
  • Femoral-popliteal lesion TASC-C or TASC-D de novo (F1 to P1)
  • Starting lesion on the superficial femoral artery and not extending beyond the intercondylar notch (P2)
  • ≥1 continuous permeable leg axis directly injecting the plantar arch
  • Rutherford 2-5
Exclusion Criteria
  • Patient under personal protection regime (tutorship, guardianship)
  • Absence of arterial axis in permeable leg
  • Patient presenting a limb acute ischaemia (chart evolving since less than 14 days)
  • Patient without favorable element to consider healing
  • History of stents on the femoropopliteal axis
  • History of femoropopliteal bypass
  • Untreated stenosis ≥30% on the iliac axis and common femoral upstream
  • Popliteal lesion beyond the intercondylar notch (P2)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Primary patency rate at 1 year.at 12 months (+/- 2months)

The permeability rate is defined by the echodoppler criteria: PVS\>2.4m/s or appearance of stenosis on the previously treated segment \>70%.

Secondary Outcome Measures
NameTimeMethod
Target vessel revascularisationat 1month (+/- 10days), 6months (+/- 1month) and 12 months (+/- 2months)

corresponds to the occurrence of a re-intervention on the previously treated artery, whatever the level, in order to maintain its permeability.

Primary patency rate at 1 year.at 1month (+/- 10days), 6months (+/- 1month)
Target lesion revascularisationat 1month (+/- 10days), 6months (+/- 1month) and 12 months (+/- 2months)

corresponds to the occurrence of a re-intervention on the treated segment to maintain or restore permeability

cost-effectiveness analysesat 12 months (+/- 2months)

Cost-effectiveness analysis between 2 therapeutic strategies: The costs related to each strategy are calculated taking into account the direct and indirect costs.

Trial Locations

Locations (1)

Insitut Coeur-Poumon, CHU

🇫🇷

Lille, France

Insitut Coeur-Poumon, CHU
🇫🇷Lille, France
Jonathan SOBOCINSKI, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.